Suppr超能文献

肾内科患者高钙血症 - 发生率、病因及对肾功能的影响。

Hypercalcemia in the nephrology department patients - incidence, etiology and impact on renal function.

机构信息

Department of Internal Medicine, Nephrology and Dialysis Therapy, Military Institute of Medicine, Warsaw, Poland.

出版信息

Pol Merkur Lekarski. 2021 Feb 24;49(289):9-12.

Abstract

UNLABELLED

Hypercalcemia (HCM) is predominantly caused by primary hyperparathyroidism (PHPT) or malignancy. It's incidence varies from 0.17% to 4.74%. Its numerous manifestations include renal symptoms.

AIM

The aim of the study was to assess the incidence and etiology of hypercalcemia in patients hospitalized at the Department of Nephrology of the Warsaw Military Institute, as well as to evaluate its impact on renal function.

MATERIALS AND METHODS

In this cross-sectional study patients admitted to the Nephrology Department of the Warsaw Military Institute between January 2017 and December 2018 were retrospectively screened for presence of HCM, defined as total calcium level or corrected calcium level in case of hypoalbuminemia >10.2 mg/dl, measured at least twice. Each patient's medical history as well as other laboratory findings were subsequently analyzed in order to establish the etiology of hypercalcemia.

RESULTS

Among 3062 hospitalisations (1993 patients) at The Department, 96 patients had elevated calcium level of which 36 were identified as hypercalcemic (1,81%). Median calcium level was 11.9 mg/dl (IQR: 11.25-13.46) with 22.24 mg/dl being the maximum observed value. Malignancy and drugs having hypercalcemizing effect were the most common etiologies identified, both being found in 9 cases (25%). Other causes of HCM included sarcoidosis, multiple myeloma (analyzed separately from other malignancies), PHPT and hypercalcemic hypocalciuria. In 7 cases HCM etiology could not be established, it therefore remained idiopathic. Acute kidney injury (AKI) developed in 20 patients (56%), in this group serum calcium levels were significantly higher than in non-AKI patients (median: 12.85 mg/dl (IQR:11.82-14.65) vs 11.25 mg/dl (IQR:10.75-11.93); p=0.0039). Additionally, chronic kidney disease (CKD) patients presented significantly lower calcium values than non-CKD patients (median: 11.47 mg/dl (IQR: 10.8-12.6) vs 13.01 mg/dl (IQR:11.9-16.08; p=0.0131).

CONCLUSIONS

Hypercalcemia is a rare disorder among Nephrology Department patients, which primary etiology is malignancy and medications having hypercalcemizing effect. Kidney injury is dependent on the severity of hypercalcemia.

摘要

目的

评估华沙军事学院肾病科住院患者高钙血症的发生率和病因,并评估其对肾功能的影响。

材料与方法

本横断面研究回顾性筛选了 2017 年 1 月至 2018 年 12 月华沙军事学院肾病科住院患者的高钙血症(定义为总钙或校正钙水平在白蛋白降低时>10.2mg/dl,至少测量两次)。随后分析每位患者的病史和其他实验室检查结果,以确定高钙血症的病因。

结果

在该科 3062 例(1993 例)住院患者中,96 例血钙升高,其中 36 例被确定为高钙血症(1.81%)。中位血钙水平为 11.9mg/dl(IQR:11.25-13.46),最高观察值为 22.24mg/dl。恶性肿瘤和具有致高钙血症作用的药物是最常见的病因,均有 9 例(25%)。其他高钙血症的病因包括结节病、多发性骨髓瘤(与其他恶性肿瘤分别分析)、甲状旁腺功能亢进症和高钙低钙尿症。7 例高钙血症的病因无法确定,因此仍为特发性。20 例(56%)患者发生急性肾损伤(AKI),该组血清钙水平明显高于非 AKI 患者(中位数:12.85mg/dl(IQR:11.82-14.65)vs 11.25mg/dl(IQR:10.75-11.93);p=0.0039)。此外,慢性肾脏病(CKD)患者的血钙值明显低于非 CKD 患者(中位数:11.47mg/dl(IQR:10.8-12.6)vs 13.01mg/dl(IQR:11.9-16.08;p=0.0131)。

结论

高钙血症是肾病科患者罕见的疾病,其主要病因是恶性肿瘤和具有致高钙血症作用的药物。肾损伤取决于高钙血症的严重程度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验